Help us help patients.

We are always looking for opportunities to partner with world class organizations to maximize the potential of our platform and develop effective therapies for patients with life-threatening conditions.

In December 2020, we entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates that are distinct from those in our internally developed pipeline. Merck has the right to select up to two collaboration targets related to next generation TCE immunotherapies for the treatment of cancer.